相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
Andrea Giustina et al.
PLOS ONE (2012)
Elevated incidence of sleep apnoea in acromegaly-correlation to disease activity
J. Roemmler et al.
SLEEP AND BREATHING (2012)
Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone
Aart-Jan van der Lely et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Current management practices for acromegaly: an international survey
A. Giustina et al.
PITUITARY (2011)
Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review
Gherardo Mazziotti et al.
PITUITARY (2010)
Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study
M. Buchfelder et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly
Antonio Bianchi et al.
PITUITARY (2009)
A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly
I. M. Holdaway et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors
Sylvia L. Asa et al.
CANCER RESEARCH (2007)
Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA
Laura De Marinis et al.
PITUITARY (2007)
Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study
I. Schreiber et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Nanomedicines in the treatment of acromegaly: focus on pegvisomant
Ferdinand Roelfsema et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2006)
Growth hormone receptor antagonists: Discovery, development, and use in patients with acromegaly
JJ Kopchick et al.
ENDOCRINE REVIEWS (2002)
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
PJ Trainer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Evidence for growth hormone (GH) autoregulation in pituitary somatotrophs in GH antagonist-transgenic mice and GH receptor-deficient mice
SL Asa et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
分享论文
